Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 15 new employees as a material inducement for their employment, as per NASDAQ Listing Rule 5635(c)(4). On March 1, 2022, the employees were granted options to purchase a total of 61,090 shares at an exercise price of $23.99 per share, reflecting the closing price on that date. The options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first anniversary and subsequent vesting every six months.
Insmed Incorporated (Nasdaq: INSM) will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:10 a.m. ET. The live fireside chat will be accessible via the company's investor relations section on their website, with an archive available for 30 days post-event. Insmed focuses on treating serious and rare diseases and has launched a first-in-disease therapy approved in the U.S., Europe, and Japan. The company is also developing therapies for unmet needs in inflammatory diseases and rare pulmonary disorders.
Insmed Incorporated (Nasdaq: INSM) reported a strong fourth quarter and full-year 2021, with total revenue reaching $56.1 million for Q4 and $188.5 million for the full year, a rise from $164.4 million in 2020. The company saw ARIKAYCE net sales of $159.5 million in the U.S. and launched the product in several European markets. However, Insmed also reported a net loss of $113 million in Q4 2021, leading to a full-year loss of $434.7 million. Despite these losses, the company expects ARIKAYCE revenues to grow by at least 30% in 2022, supported by a cash position of $766.8 million.
Insmed Incorporated, a biopharmaceutical company focused on serious rare diseases, will present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 18, 2022, at 10:00 a.m. ET. The fireside chat will be available for live viewing on the company’s investor relations website and archived for 30 days post-event. Insmed’s first product targets chronic lung disease, with ongoing research into therapies for neutrophil-mediated inflammatory diseases and rare pulmonary conditions. The company is based in Bridgewater, New Jersey.
Insmed Incorporated announced the granting of inducement awards to 10 new employees as part of their recruitment strategy. Each employee received options to purchase a total of 74,410 shares of common stock at an exercise price of $23.71, aligning with the market closing price on February 1, 2022. The options have a 10-year term with a four-year vesting schedule. Insmed focuses on transforming lives through treatments for serious and rare diseases, and it is advancing a pipeline targeting unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) will announce its fourth quarter and full year 2021 financial results on February 17, 2022. Management will also provide a business and pipeline update during a conference call from 8:00 to 9:30 a.m. ET. Interested parties can join by calling specified numbers or via webcast on the company's website. A replay of the call will be available for a month. Insmed's mission is to improve lives with therapies for serious diseases, and it has a robust pipeline addressing unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:45 p.m. ET. The event will be available via live webcast on the company's website, with an archived version accessible for 30 days post-event. Insmed is focused on transforming the lives of patients with serious and rare diseases, notably with its first commercial product targeting a chronic lung disease and an expanding pipeline for unmet needs.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to six new employees, totaling 43,610 stock options exercisable at $26.69 per share. These options come with a ten-year term and a four-year vesting schedule, with 25% vesting after one year and the remainder vesting semi-annually thereafter. This move, compliant with NASDAQ Listing Rule 5635(c)(4), aims to attract talent into the company. Insmed focuses on treating serious and rare diseases, with an approved therapy for a chronic lung disease and a pipeline of investigational therapies.
Insmed has announced the grant of inducement awards to 15 new employees, approved by its Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 52,180 shares at an exercise price of $31.05, the closing price as of November 1, 2021. The options have a ten-year term and will vest over four years, with the first 25% vesting after one year, followed by 12.5% every six months. Insmed aims to improve the lives of patients with serious and rare diseases and continues expanding its pipeline of therapies.
Insmed Incorporated (Nasdaq: INSM) announced its participation in three upcoming virtual investor conferences aimed at discussing the company's developments in biopharmaceuticals. On November 9, 2021, at 10:30 a.m. ET, Insmed will join the Credit Suisse 30th Annual Virtual Healthcare Conference. This will be followed by the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 8:40 a.m. ET, and the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 8:00 a.m. ET. All events will be webcast live and archived for 30 days.